We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA: Overall Survival is Key to NSCLC Treatment Approval
FDA: Overall Survival is Key to NSCLC Treatment Approval
June 17, 2011
Overall survival (OS) should be the standard clinical endpoint used to establish efficacy in non-small cell lung cancer (NSCLC) trials, a draft FDA guidance says.